57748-41-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-PYRIDINYLMETHOXY)BENZALDEHYDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its unique chemical structure allows it to be a key component in the creation of various medicinal compounds.
Used in Dye Industry:
In the dye industry, 4-(2-PYRIDINYLMETHOXY)BENZALDEHYDE is used as an intermediate for the production of dyes, where its aromatic aldehyde properties contribute to the color and stability of the dyes.
Used in Organic Compounds Synthesis:
4-(2-PYRIDINYLMETHOXY)BENZALDEHYDE is used as a building block for the production of various heterocyclic compounds and fine chemicals, highlighting its importance in the synthesis of complex organic molecules.
Used in Biological and Pharmacological Research:
4-(2-PYRIDINYLMETHOXY)BENZALDEHYDE is studied for its potential biological and pharmacological activities, such as its antifungal and antibacterial properties, making it a candidate for research in new treatments and therapies.
Overall, 4-(2-PYRIDINYLMETHOXY)BENZALDEHYDE's applications span across multiple industries, showcasing its significance in both the synthesis of various compounds and in the exploration of its intrinsic biological properties.

InChI:InChI=1/C13H11NO2/c15-9-11-4-6-13(7-5-11)16-10-12-3-1-2-8-14-12/h1-9H,10H2

Upstream product

• 4377-33-7 2-chloromethylpyridine 
• 123-08-0 4-hydroxy-benzaldehyde 
• 586-98-1 2-Hydroxymethylpyridine 
• 6959-47-3 2-chloromethylpyridine hydrochloride 

Downstream Products

• 1025944-88-0 O-{cyclohexyl-[4-(pyridin-2-ylmethoxy)-phenyl]-methyl}-hydroxylamine 
• 1221413-74-6 5-(4-(pyridin-2-ylmethoxy)benzylidene)thiazolidine-2,4-dione 
• 1426854-96-7 meso-[4-(pyridin-2-ylmethoxy)phenyl]dipyrromethene 
• 1402728-74-8 (1E,6E)-1-(1H-indol-6-yl)-7-[4-(2-pyridylmethoxy)phenyl]hepta-1,6-diene-3,5-dione 
• 1402728-60-2 (1E,6E)-1-(1H-indol-5-yl)-7-[4-(2-pyridylmethoxy)phenyl]hepta-1,6-diene-3,5-dione 
• 1402728-68-0 (1E,6E)-1-(1H-indol-3-yl)-7-[4-(2-pyridylmethoxy)phenyl]hepta-1,6-diene-3,5-dione 

Relevant academic research and scientific papers

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Design, synthesis, antitrypanosomal activity, DNA/RNA binding and in vitro ADME profiling of novel imidazoline-substituted 2-arylbenzimidazoles

Novel imidazoline benzimidazole derivatives containing diversely substituted phenoxy moieties were synthesized with the aim of evaluating their antitrypanosomal activity, DNA/RNA binding affinity and in vitro ADME properties. The presence of the diethylaminoethyl subunit in 18a–18c led to enhanced antitrypanosomal potency, particularly for 18a and 18c, which contain unsubstituted and methoxy-substituted phenoxy moieties. They were found to be > 2-fold more potent against African trypanosomes than nifurtimox. Fluorescence and CD spectroscopy, thermal denaturation assays and computational analysis indicated a preference of 18a–18c toward AT-rich DNA and their minor groove binding mode. Replacement of the amidine group with less basic and ionisable nitrogen-containing moieties failed to improve membrane permeability of the investigated compounds. Due to structural diversification, the compounds displayed a range of physico-chemical features resulting in variable in vitro ADME properties, leaving space for further optimization of the biological profiles.

NOVEL PYRAZOLE DERIVATIVE

Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.

NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF

The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.

Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors

Prostaglandins have a short life in vivo because they are metabolized rapidly by oxidation to 15-ketoprostaglandins catalyzed by a cytosolic enzyme known as NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, CT-8, a thiazolidinedione analogue, was found to be a potent inhibitor of 15-PGDH. Structure-activity analysis indicated that the N-methylation of thiazolidine-2,4-dione, CT-8, abolished the inhibitory activity, whereas the introduction of an ethyl hydroxyl group at amine in CT-8 still had a good inhibitory effect. Based on the structures of the thiazolidinediones analogues and inhibitory activity, a range of benzylidene thiazolidinedione derivatives were synthesized with different substituents on the phenyl ring and their inhibitory activity was evaluated. Replacement of the cyclohexylethyl group of CT-8 with the hetero five-member ring increased the inhibitory potency. However, replacement of the cyclohexylethyl group with a hetero six-member ring decreased the inhibitory potency significantly. It was found that compound 2 (5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione) was the most potent inhibitor that was effective in the nanomolar range.

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors

A novel series of heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids was studied as leukotriene biosynthesis inhibitors. A hypothesis of structure-activity optimization by insertion of an oxime moiety was investigated using REV-5901 as a starting point. A systematic structure- activity optimization showed that the spatial arrangement and stereochemistry of the oxime insertion unit proved to be important for inhibitory activity. The promising lead, S-(E)-11, inhibited LTB4 biosynthesis in the intact human neutrophil with IC50 of 8 nM and had superior oral activity in vivo, in a rat pleurisy model (ED50 = 0.14 mg/kg) and rat anaphylaxis model (ED50 = 0.13 mg/kg). In a model of lung inflammation, S-(E)-11 blocked LTE4 biosynthesis (ED50 of 0.1 mg/kg) and eosinophil influx (ED50 of 0.2 mg/kg). S-(E)-11 (A-93178) was selected for further preclinical evaluation.